Hyperkalemia Is an Underestimated Risk Factor in COPD
International Journal of Chronic Obstructive Pulmonary Disease · 2025
DOI: 10.2147/copd.s490620 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Jukka Mäenpää und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chief Medical Office, Research & Development, Patient Safety Biopharma, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Hyperkalemia, Potassium, Lung. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: COPD
Abstract (Originalsprache)
Background
Hyperkalemia increases mortality in various patient populations. The risk of hyperkalemia in COPD patients is poorly recognized. Hyperkalemia may increase cardiovascular mortality during and soon after COPD exacerbations. Patients and Methods: A cohort based on two clinical trials comprising 7968 patients with moderate-to-very severe COPD was analysed retrospectively for associations between hyperkalemia and common comorbidities such as chronic kidney disease, diabetes mellitus (DM), or renin-angiotensin-aldosterone system inhibitor use.
Results
Overall, 6.4% of 7968 patients had hyperkalemia (5.3% Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2, 6.8% GOLD 3, and 8.0% GOLD 4). COPD severity was associated with significantly higher hyperkalemia risk in GOLD 3 (odds ratio [OR]=1.28, 95% CI 1.04-1.58) and GOLD 4 (OR=1.64, 95% CI 1.19-2.22) versus GOLD 2 patients. Hyperkalemia cases increased with decreasing renal function. Patients with moderate-to-severe renal impairment had >2-fold increased hyperkalemia risk versus those with normal renal function (OR=2.29, 95% CI 1.71-3.04). DM was associated with increased hyperkalemia risk (OR=1.28, 95% CI 1.02-1.59). Angiotensin-converting-enzyme inhibitor (ACEi) use increased hyperkalemia risk (OR=1.25, 95% CI 1.02-1.53). Unexpectedly, the association between hyperkalemia and renin-angiotensin-aldosterone system inhibitor use was statistically significant only in the normal renal function group (OR=1.63, 95% CI 1.13-2.34).
Conclusion
Hyperkalemia risk is higher in severe and very severe COPD patients than patients with moderate COPD. Hyperkalemia was also associated with decreasing kidney function, DM, and ACEi use. Serum potassium levels should be monitored regularly in patients with COPD, particularly those with GOLD-3 and 4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chief Medical Office, Research & Development, Patient Safety Biopharma, AstraZeneca, Gothenburg, Sweden.
- Patient Safety Operations, Technology & Analytics, Global Patient Safety, AstraZeneca, Macclesfield, UK.
- BioPharmaceuticals, Early Clinical Development, AstraZeneca, Gaithersburg, MD, USA.
- BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
- Cardiovascular Safety Center of Excellence and Safety Knowledge Groups, Global Patient Safety, AstraZeneca, Cambridge, UK.
- BioPharma Late-Stage Development Respiratory & Immunology, Biometrics and Statistical Innovation, AstraZeneca, Gothenburg, Sweden.
Zitieren
APA
Mäenpää, J., Anderson, I., Owen, C. A., Emerath, U., Hughes, R., Sultana, S. R., & Olsson, M. (2025). Hyperkalemia Is an Underestimated Risk Factor in COPD. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s490620
Vancouver
Mäenpää J, Anderson I, Owen CA, Emerath U, Hughes R, Sultana SR, et al. Hyperkalemia Is an Underestimated Risk Factor in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s490620
BibTeX
@article{Menp2025,
author = {Mäenpää, Jukka and Anderson, Isobel and Owen, Caroline A and Emerath, Ulrika and Hughes, Rod and Sultana, Stefan R and Olsson, Marita},
title = {Hyperkalemia Is an Underestimated Risk Factor in COPD},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2025},
doi = {10.2147/copd.s490620}
}
EUVIMED